



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

08/982272

V8

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
08/982,272	12/01/97	KIPPS	T 221/003 EXAMINER

LYON & LYON LLP
633 W FIFTH ST.,
SUITE 4700
LOS ANGELES CA 90071

HM12/0608

ART. UNIT	PAPER NUMBER
GARIBEL, P	1644 19

DATE MAILED:

06/08/00

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

Responsive to communication(s) filed on 3/6/00

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 1 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

Claim(s) 1-86 is/are pending in the application.
Of the above, claim(s) 11-66, 68-86 is/are withdrawn from consideration.

Claim(s) _____ is/are allowed.

Claim(s) _____ is/are rejected.

Claim(s) _____ is/are objected to.

Claim(s) 1-10, 67, 83-86 are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on _____ is/are objected to by the Examiner.

The proposed drawing correction, filed on _____ is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All Some* None of the CERTIFIED copies of the priority documents have been:

received.

received in Application No. (Series Code/Serial Number) _____.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____.

Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

Notice of Reference Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

-SEE OFFICE ACTION ON THE FOLLOWING PAGES-

Serial No. 08/982272
Art Unit 1644

DETAILED ACTION

1. Applicant is reminded that the Art Unit location of your application in the PTO has been changed to Art Unit 1644. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1644, Technology Center 1600.
2. The request filed 3/6/00 (Paper No. 17) for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 08/982,272 is acceptable and a CPA has been established. An Office Action on the CPA follows.

Claims 1 and 83 have been amended.
Claims 84-86 have been added.

Claims 1-10, 67 and 83-86 are being acted upon as the elected invention.

Claims 11-66, 68-82 and the non-elected species have been withdrawn from further consideration by the examiner, 37 C.F.R. § 1.142(b) as being drawn to the nonelected inventions.

3. Given applicant's newly added claims the following species election is noted as it applies to the originally presented invention, encompassed by claims 1-10 and 67, 83-86.

It appears that applicant maintains the election of the species of "a ligand that is a member of the tumor necrosis factor family" which is "CD40 ligand"

4. In addition, this application contains claims directed to the following patentably distinct species of the originally present invention of Group I: wherein the accessory molecule specificity is:

- A) CD40 ligand alone as the accessory molecule ligand,
- B) a chimeric accessory ligand comprising CD40L and Fas-ligand,
- C) a chimeric accessory ligand comprising CD40L and CD70,
- D) a chimeric accessory ligand comprising CD40L and TNF α ,
- E) a chimeric accessory ligand comprising CD40L and TNF β ,
- F) a chimeric accessory ligand comprising CD40L and CD30 ligand,
- G) a chimeric accessory ligand comprising CD40L and 4-1BB ligand,
- H) a chimeric accessory ligand comprising CD40L and TRAIL, or
- I) a chimeric accessory ligand comprising CD40L and nerve growth factor.

These species are distinct because their structures, interactions, modes of action are different.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

5. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Serial No. 08/982272

Art Unit 1644

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

6. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Phillip Gambel
Phillip Gambel, PhD.
Primary Examiner
Technology Center 1600
June 7, 2000